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Background: Cognitive Stimulation Therapy (CST) is effective and cost-effective for people with mild-to-
moderate dementia when delivered biweekly over 7 weeks.
Aims: To examine whether longer-term (maintenance) CST is cost-effective when added to usual care.
Methods: Cost-effectiveness analysis within multicenter, single-blind, pragmatic randomized controlled
trial; subgroup analysis for people taking acetylcholinesterase inhibitors (ACHEIs). A total of 236 par-
ticipants with mild-to-moderate dementia received CST for 7 weeks. They were randomized to either
weekly maintenance CST added to usual care or usual care alone for 24 weeks.
Results: Although outcome gains were modest over 6 months, maintenance CST appeared cost-effective
when looking at self-rated quality of life as primary outcome, and cognition (MMSE) and proxy-rated
quality-adjusted life years as secondary outcomes. CST in combination with ACHEIs offered cost-
effectiveness gains when outcome was measured as cognition.
Conclusions: Continuation of CST is likely to be cost-effective for people with mild-to-moderate dementia.
 2015 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/3.0/).Cognitive stimulation therapy (CST) is an evidence-based, group
intervention for people with mild-to-moderate dementia, involving
themed activities to stimulate cognitive function. It is both effective
and cost-effective when delivered biweekly over 7 weeks.1e3 Would
continuation of CST for longer generate additional advantages? Evi-
dence from a pilot study of continued CST suggested improvements in
cognitive function.4the sales of the Making a
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(MCST), delivered weekly for 24 weeks (plus usual care), improved
patient quality of life compared with usual care alone.5 It also found
that MCST improves cognition for people with dementia taking
acetylcholinesterase inhibitor medication (ACHEIs). Given intensi-
fying pressure on health and social care resources, a key question
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tive stimulation is also cost-effective.6
Methods
Centers
Eighteen centers were recruited in London, Essex, and Bed-
fordshire: 9 care homes and 9 community centers (day centers,
community mental health teams, and voluntary organizations).
Another 3 centers were approached: 1 refused and 2 were excluded
because they had insufﬁcient participants meeting inclusion criteria.
The study has received ethical approval by the Barking & Havering
Local Research Ethics Committee, reference number 08/H0702/68 in
October 2008.
Participants
Participants were eligible for inclusion if they met DSM-IV criteria
for dementia,7 scored between 0.5 and 2.0 (mild-to-moderate) on the
Clinical Dementia Rating (CDR),8 could communicate in English, could
see and hear well enough to participate in CST, did not have major
physical illness or disability (eg, urinary tract infection, delirium, or
stroke) that could affect participation, or have a diagnosed learning
disability.
Design
Participants completed 7 weeks of standard CST (14 twice-weekly
sessions of 45 minutes), and were then immediately entered into a
single-blind, multicenter, pragmatic randomized controlled trial
comparing MCST added to usual care with usual care alone. There was
no modiﬁcation in design or eligibility criteria from the study
protocol.9
Randomization
Participants were randomized to either the intervention group
receiving weekly MCST for 24 weeks in addition to usual care or the
control group receiving usual care alone.5 Although usual care did not
include any intervention similar to MCST, care offered to participants
varied among centers. Participants were randomized in equal pro-
portions after stratifying for center, whether ACHEI was prescribed,
and previous CST group. Data storage and transfer were performed to
avoid contamination. The nature of the intervention precluded
blinding of participants, but researchers conducting interviews and
the statistician analyzing outcomes were blind to group assignment.
Researchers conducting the economic evaluation were not blind to
assignment.
Outcome Measures
Participants were assessed at baseline (before randomization),
after 3 months (intermediate end point), and after 6 months (primary
end point).
There were 2 primary outcomes:
 cognition measured by ADAS-Cog (Alzheimer’s Disease
Assessment Scale-Cognition subscale): lower scores reﬂect
better cognition10
 quality of life measured by QoL-AD (Quality of Life-Alzheimer’s
Disease scale): higher scores reﬂect better quality of life11
Secondary outcomes were Mini-Mental State Examination (MMSE): higher scores reﬂect
better cognition12
 Neuropsychiatric Inventory (NPI): lower scores reﬂect better
behavior13
 ADCS-ADL (Alzheimer’s Disease Co-operative StudydActivities
of Daily Living Inventory): higher scores reﬂect greater ability
in activities of daily living (ADLs)14
 DEMQOL, a dementia-speciﬁc quality-of-life scale completed
by participants (self-report), family carers, or care center
workers (proxy): higher scores indicate better quality of life15
 proxy version of QoL-AD, completed by family carers or care
center workers: higher scores reﬂect better quality of life11
 EQ-5D-3L, a generic health-related quality of life measure
completed by participants (self-report), family carers or care
center workers (proxy)16
Utility values were calculated from both generic and dementia-
speciﬁc quality of life measures) to compare gain in quality-
adjusted life years (QALYs) using both participant-reported and
proxy-reported measures. QALYs were calculated from EQ-5D and
Proxy EQ-5D using societal weights, York A1 Tariff,17 by combining
ratings on mobility, self-care, usual activities, pain/discomfort, and
anxiety and depression domains to calculate utility values. QALYs
were also calculated from dementia-speciﬁc measures (DEMQOL-U
and DEMQOL-PROXY-U) using an algorithm based on societal
weights.18 QALYs were calculated by “area under the curve” analysis,
with linear interpolation between assessment points.
Previous ﬁndings19 suggest that a difference in score of 1.4 points
on the MMSE can be considered “minimum clinically important.” We
could not ﬁnd suggestions for clinically important differences on the
other measures.
Resource Use and Cost Measures
The Client Service Receipt Inventory20 was adapted to capture
data on all health and social care services used in the previous
3 months by participants and inputs from unpaid family and other
carers. It was completed with family carers or center care workers 3
times (at randomization, 3 months and at 6 months).
Unit costs reﬂected long-run marginal opportunity costs, taken
from the Personal Social Services Research Unit (PSSRU) compendium
for 2011.21 We discounted at 3.5% for items providing beneﬁt for more
than 1 year, such as equipment or adaptations. Medication costs came
from the British National Formulary.22 Costs for equipment and ad-
aptations came from market sources. Where necessary, unit costs
were adjusted to 2011 prices using the Consumer Price Index.
Calculating the cost of MCST itself took into account the 1-day
training course for facilitators (averaging £1.50 per subsequent
MCST session, assuming skills acquired lasted 5 years), material and
equipment used at each session (£1 per MCST session), and costs of
the 2 cofacilitators (1 researcher, costing £130 per session; 1 care
worker, costing £25 per session; the difference is due to preparation
and travel time). Transport costs were added for participants who
traveled to community centers for sessions and requested travel re-
funds (average £1.44 per person per session).
Average total cost per MCST session was £157.46 in care homes
and £158.90 in community centers. Average number of participants
per session was 5.
Cost-Effectiveness Analyses
Themain cost-effectiveness analyseswere conducted froma health
and social care perspective. Further analyses added costs for unpaid
carer time (societal perspective). The primary economic evaluation
measured effectiveness by, in turn, each primary outcome as stated in
Table 1
Use of Services, Equipment, Adaptations, and Medications by Allocation Group and
Time Point
Variable Control Intervention
Prebaseline (7 wk)
Residential care 56 54% 56 49%
Hospital services 24 23% 32 28%
Day services 85 82% 98 86%
Equipment and adaptations 13 13% 17 15%
Community services 36 35% 53 46%
Medications 97 93% 110 96%
n 104 100% 114 100%
1e3 mo
Residential care 56 54% 55 48%
Hospital services 39 38% 39 34%
Day services 84 81% 95 83%
Equipment and adaptations 17 16% 15 13%
Community services 44 42% 56 49%
Medications 102 98% 109 96%
n 104 100% 114 100%
4e6 mo
Residential care 49 53% 49 46%
Hospital services 30 32% 35 33%
Day services 77 83% 92 87%
Equipment and adaptations 11 12% 17 16%
Community services 37 40% 52 49%
Medications 88 95% 102 96%
n 93 100% 106 100%
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tional cost to the health and social care system of achieving a 1-point
difference in each outcome from adding MCST to usual care.
Secondary economic evaluations were cost-utility analyses, again
from each perspective, using utilities computed ﬁrst from EQ-5D and
Proxy EQ-5D, and then from DEMQOL and Proxy DEMQOL. These
secondary analyses show the cost of achieving 1 additional QALY
from adding MCST to usual care.
We also conducted cost-consequences analyses, looking at other
secondary outcomes (MMSE, ADCS-ADL, proxy QoL-AD) alongside
costs.
There were 4 potential results from each cost-effectiveness
analysis:
1. MCST is less costly and more effective than usual care: the
decision-maker would be attracted to MCST;
2. MCST is more costly and less effective than usual care: the
decision-maker would be unlikely to recommend, commission,
or deliver MCST;
3. MCST is less costly but less effective than usual care; and
4. MCST is more costly and more effective than usual care.
If MCST is less costly and more effective than usual care, or is more
costly and less effective, then advice to the decision-maker is generally
straightforward, although measurement error generates some uncer-
tainty. However, if MCST is cheaper but less effective, or if MCST is
more expensive but also more effective, the decision-maker must
weigh up the outcome and cost differences; the decision will depend
on the value attached to differences in outcome. In these circum-
stances we calculate the incremental cost-effectiveness ratio (ICER):
ICER ¼ DC=DE;
where DC is difference in mean costs betweenMCSTand usual care,
and DE is mean difference in outcome.
ICERs were estimated with the Seemingly Unrelated Regression
(SUR) model using Stata (Stata Corp, College Station, TX). Each cost
and outcome measure in turn was included in a bivariate system that
implemented a regression on treatment allocation (MCST or usual
care), controlling for participant age at baseline, gender, ethnicity,
marital status, whether or not taking ACHEIs, CDR score at baseline,
having a staff (paid) or family (unpaid) carer, center type (community
or care home), and center (location). Cost equations also controlled
for cost in the 7-week period before baseline (obtained by stan-
dardizing 3-month retrospective baseline data), and each outcome
equation controlled for the corresponding measure at baseline.
Multiple imputation was used for missing data.23 Incremental cost
and outcome coefﬁcients and their correlation were estimated with
1000 bootstrap replications to address possible skewness. Using a
series of hypothetical values for willingness-to-pay (l) for 1 addi-
tional unit of outcome (eg, a 1-point difference in ADAS-Cog), net-
beneﬁts (NB) were calculated as:
NB ¼ lDE DC
The range of willingness-to-pay values was £0 to £6000 for all
outcomemeasures except the QALY (£0 to £100,000). Resultant net-
beneﬁt values were used to plot cost-effectiveness acceptability
curves (CEACs), showing the probability that MCST is a cost-
effective addition to usual care. Probability values were derived
from the normal cumulative distribution of NBs.
An advantage of using the SUR method is a gain in efﬁciency
compared with ordinary least-squares regression methods.24
In additional subgroup analyses, we examined whether there was
complementarity between MCST and use of ACHEI medications by
adding an interaction term to the regressions.Sensitivity Analysis
We explored a societal perspective rather than health and social
care perspective: we attached a cost to unpaid care time assuming an
opportunity cost approach, with each hour of unpaid care set equal to
national minimum wage (£6.00 per hour), which could represent the
opportunity cost to carers of providing support, assuming they could
alternatively be in employment.
A further sensitivity analysis examined cost-effectiveness after
adjusting intervention costs to more closely resemble those expected
outside a trial. The intervention cost would be lower, because MCST
would be delivered by 2 members of staff in the care setting (costing
£25 per session), with 1 taking 30 minutes to plan the session, an
additional cost of £12.50 per session. It is also expected that staff will
train for the intervention by reading the Maintenance CST manual5 as
opposed to receiving face-to-face training, as in the main analysis,
eliminating the training cost component. In this scenario, average
total cost per MCST session is £63.78 in care homes and £65.22 in
community centers (less than half the cost in the main analysis).
However, we cannot estimate the impact that these changes
would have on the outcomes from CST, and so adjusting costs down
can only be a partial sensitivity analysis.
Results
Participant Characteristics
Data were collected for 236 people at baseline, 218 at 3 months
and 199 at 6 months. Randomization produced relatively well-
balanced samples: there was a slight imbalance with regard to
marital status.5
Outcomes
At 6 months, self-rated quality of life measured by QoL-AD was
higher for the MCST group than for controls, but there was no
intergroup difference in cognition measured (ADAS-Cog or any sec-
ondary outcomes). At 3 months, there were no intergroup differences
Table 2
Health and Social Care and Societal Perspective Costs, Including Intervention Costs, by Allocation Group and Time Point
Control Intervention Difference Between the Groups
Mean (SD) Mean (SD) Mean Difference P Value Adjusted P Value
Health and social care perspective
Prebaseline (7 wk), n 104 114
Residential care 2688.6 (2682.5) 2380.1 (2643.6) 308.5 .4 .33
Hospital services 84.7 (274.2) 73.4 (215.2) 11.3 .73 .65
Day services 172.6 (325.3) 193.7 (389.7) 21.1 .66 .86
Equipment and adaptations 2 (7.3) 2.3 (7.6) 0.3 .76 .73
Community services 185.4 (338.8) 218.9 (310.4) 33.5 .44 .72
Medications 98.4 (88.3) 127.4 (97) 29 .02 .02
CST intervention 174.2 (68.1) 164.2 (54.7) 10 .23 .51
Total costs 3405.9 (2407) 3160 (2383.7) 245.9 .45 .36
1e3 mo, n 104 114
Residential care 4563.9 (4513.5) 4072.2 (4564.8) 491.7 .42 .36
Hospital services 164.4 (425.4) 169.3 (433.2) 4.9 .93 .88
Day services 401.6 (920.6) 440.1 (894.7) 38.5 .75 .82
Equipment and adaptations 8.8 (39.6) 8.8 (44.1) 0 1 .94
Community services 509.7 (872.6) 494.1 (741.8) 15.6 .89 .14
Medications 178.6 (146.1) 197.2 (147.5) 18.6 .34 .45
MCST intervention d 299.9 (140.4) d d d
Total costs 5826.9 (4083.5) 5681.5 (4062.4) 145.4 .79 .14
4e6 mo, n 93 106
Residential care 4591.1 (4615.7) 4023.1 (4571.9) 568 .38 .4
Hospital services 142.5 (386) 147.7 (407.9) 5.2 .93 .95
Day services 280.4 (623.2) 421.1 (991.7) 140.7 .22 .33
Equipment and adaptations 10.9 (45) 6 (16.3) 4.9 .33 .29
Community services 473.3 (847.6) 471.6 (740.2) 1.7 .99 .09
Medications 193.8 (163.5) 194.8 (140.4) 1 .97 .94
MCST intervention d 322.5 (224.5) d d d
Total costs 5692 (4132.7) 5586.8 (4033.7) 105.2 .86 .53
1e6 mo, n 93 106
Residential care 9116.4 (8930.7) 8157.8 (9092) 958.6 .45 .94
Hospital services 268.7 (497.8) 302.2 (569.4) 33.5 .66 .7
Day services 696.1 (1471) 858.5 (1646) 162.4 .47 .77
Equipment and adaptations 20.3 (84.2) 14.1 (52.9) 6.2 .54 .37
Community services 963.4 (1662.1) 958.2 (1397.2) 5.2 .98 .09
Medications 375.1 (289.6) 391.2 (269.5) 16.1 .68 .9
MCST intervention d 623.8 (341.4) d d d
Total costs 11440 (7971.6) 11305.7 (7873) 134.3 .91 .24
Societal perspective
Prebaseline (7 wk), n 104 114
Total health and social care costs 3405.9 (2407) 3160 (2383.7) 245.9 .45 .36
Unpaid carer costs 680.3 (1126.6) 1053.5 (1659.8) 373.2 .05 .03
Total societal costs 4086.2 (1982.2) 4213.5 (2036.3) 127.3 .64 .02
1e3 mo, n 104 114
Total health and social care costs 5826.9 (4083.5) 5681.5 (4062.4) 145.4 .79 .14
Unpaid carer costs 1655 (3163.8) 2572.2 (3894.2) 917.3 .05 .1
Total societal costs 7481.9 (3517.2) 8253.7 (3549.8) 771.8 .11 .02
4e6 mo, n 93 106
Total health and social care costs 5692 (4132.7) 5586.8 (4033.7) 105.2 .86 .53
Unpaid carer costs 2053.1 (3666.7) 2820.4 (4228.2) 767.3 .17 .78
Total societal costs 7745.2 (3633) 8407.2 (3680.9) 662.1 .2 .56
1e6 mo, n 93 106
Total health and social care costs 11440 (7971.6) 11305.7 (7873) 134.3 .91 .24
Unpaid carer costs 3752.4 (6416.2) 5504.4 (8089.7) 1752 .08 .34
Total societal costs 15192.4 (6294.1) 16810.1 (6757.7) 1617.7 .08 .12
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better proxy-rated quality of life (both QoL-AD and DEMQOL) and
ADLs (ADCS-ADL).5Service Use
The groups are quite balanced at baseline in relation to service
utilization (Table 1), although the usual care group make more use of
residential services, and symmetrically less use of community ser-
vices. This gap in residential care use widened slightly post-baseline.
This intergroup difference was not a randomization failure, but a
consequence of sample attrition: individuals in the intervention
group were less likely to drop out of the study if living in thecommunity and more likely to drop out if living in a care home. It
may be that individuals in the community received more support
from their family carers to participate.
Over the study period, there were few changes in service use
patterns, except that both groups used more hospital services.Costs
Cost of MCST itself averaged £623 per participant. Looking across
all health and social care service costs, residential care was the single
largest single item (Table 2). Consistent with service use patterns,
average residential care costs looked slightly higher in the control
than intervention group because slightly more people in the usual
Table 3
Incremental Cost-Effectiveness Ratios Over 1 to 6 Months
Incremental Cost Incremental Effect ICER
(£, 2010/11) Mean [95% Bootstrap CI] Mean [95% Bootstrap CI]
MCST vs TAU (health and social care perspective)
1e6 mo
ADAS-Cog 473.89 [e315.45e1263.23] 0.65 [e4.08e2.77] TAU dominant
QoL-AD 473.46 [e315.61e1262.53] 1.78 [e0.39e3.95] 266
MMSE 474.01 [e316.15e1264.17] 0.85 [e0.48e2.18] 558
ADCS-ADL 471.57 [e317.67e1260.81] 0.95 [e2.50e4.39] 498
Proxy QoL-AD 472.70 [e314.60e1260.01] 0.07 [e1.63e1.76] 7050
Proxy DEMQOL 472.31 [e338.46e1283.07] 1.13 [e2.48e4.74] 419
QALY (EQ-5D) 474.81 [e314.38e1263.99] 0.0013 [e0.0200e0.0223] 365,276
QALY (Proxy EQ-5D) 473.60 [e315.48e1262.68] 0.0176 [e0.0050e0.0403] 26,835
QALY (DEMQOL) 518.39 [e346.60e1383.39] 0.0039 [e0.0092e0.0170] 132,539
QALY (Proxy DEMQOL) 401.52 [e441.99e1245.04] 0.0062 [e0.0049e0.0173] 64,785
ACHEIs/MCST vs ACHEIs
1e6 mo
ADAS-Cog 465.57 [e781.21e1712.35] 0.74 [e7.86e9.34] 630
QoL-AD 466.17 [e780.11e1712.45] 0.78 [e3.76e5.33] 597
MMSE 465.55 [e781.46e1712.55] 2.63 [e0.97e6.22] 177
ADCS-ADL 468.22 [e777.54e1713.97] 1.47 [e7.63e10.57] 319
Proxy QoL-AD 466.90 [e779.24e1713.03] 0.37 [e4.90e4.16] ACHEIs dominant
Proxy DEMQOL 468.75 [e779.83e1717.33] 4.81 [e7.11e16.74] 97
QALY (EQ-5D) 464.72 [e783.02e1712.46] 0.0257 [e0.0178e0.0692] 18,068
QALY (Proxy EQ-5D) 465.88 [e780.99e1712.75] 0.0262 [e0.0190e0.0714] 17,787
QALY (DEMQOL) 494.01 [e819.14e1807.17] 0.0004 [e0.0498e0.0505] 1,308,421
QALY (Proxy DEMQOL) 360.43 [e913.85e1634.72] 0.0025 [e0.0304e0.0354] 143,979
MCST vs TAU (societal perspective)
1e6 mo
ADAS-Cog 1143.07 [e336.50e2622.63] 0.64 [e4.06e2.79] TAU dominant
QoL-AD 1143.14 [e335.45e2621.73] 1.78 [e0.40e3.95] 643
MMSE 1145.46 [e333.57e2624.50] 0.85 [e0.48e2.18] 1350
ADCS-ADL 1137.30 [e344.55e2619.15] 0.98 [e2.50e4.46] 1162
Proxy QoL-AD 1138.41 [e340.40e2617.23] 0.07 [e1.62e1.76] 15,258
Proxy DEMQOL 1137.73 [e356.55e2632.02] 1.13 [e2.48e4.74] 1004
QALY (EQ-5D) 1145.72 [e332.72e2624.16] 0.0013 [e0.0197e0.0222] 882,801
QALY (Proxy EQ-5D) 1142.78 [e338.64e2624.20] 0.0176 [e0.0050e0.0403] 64,842
QALY (DEMQOL) 1574.56 [e176.49e3325.60] 0.0039 [e0.0092e0.0171] 400,993
QALY (Proxy DEMQOL) 1259.07 [252.22e 2770.36] 0.0061 [e0.0050e0.0173] 205,079
MCST vs TAU (implementation of the intervention “in practice”)
1e6 mo
ADAS-Cog 121.04 [e669.32e911.39] 0.65 [e4.08e2.77] Usual care dominant
QoL-AD 120.56 [e669.51e910.64] 1.78 [e0.39e3.95] 68
MMSE 121.20 [e669.91e912.31] 0.85 [e0.48e2.18] 143
ADCS-ADL 118.81 [e671.40e909.01] 0.95 [e2.50e4.39] 126
Proxy QoL-AD 119.81 [e668.30e907.91] 0.07 [e1.63e1.76] 1786
Proxy DEMQOL 117.07 [e693.74e927.88] 1.13 [e2.48e4.74] 104
QALY (EQ-5D) 122.08 [e668.07e912.23] 0.0013 [e0.0200e0.0223] 93,912
QALY (Proxy EQ-5D) 120.74 [e669.30e910.78] 0.0176 [e0.0050e0.0403] 6841
QALY (DEMQOL) 162.13 [e701.89e1026.15] 0.0039 [e0.0092e0.0170] 41,425
QALY (Proxy DEMQOL) 47.51 [e797.21e892.24] 0.0062 [e0.0049e0.0173] 7666
TAU, Treatment as Usual.
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was not statistically signiﬁcant. In fact, the only signiﬁcant cost dif-
ference between MCST and usual careeonly groups was for medica-
tions (at baseline only).
Total health and social care costs over 6 months were slightly
but not signiﬁcantly lower for the MCST group (£11,306 vs £11,440);
however, this comparison does not adjust for baseline covariates, in
particular that the MCST group had slightly lower costs than the
usual careeonly group before baseline. The cost-effectiveness an-
alyses adjusted for these covariates, showing that the intervention
group was more costly than the control group (see the next
section).
Cost-Effectiveness (at 6 Months)
By 6 months, and after adjustment for baseline covariates, par-
ticipants receiving MCST plus usual care had slightly but not signiﬁ-
cantly higher health and social care costs than participants receivingusual care alone. The adjusted intergroup cost difference ranges be-
tween £401 and £518 (Table 3) depending on the outcome being
analyzed (because this affects baseline measures used in statistical
adjustment).
Combining costs and outcomes we generate the ICERs (Table 3).
Mean cost per 1-point difference on QoL-AD was £266. Looking at the
CEAC for this outcome, the probability that MCST would be seen as
cost-effective is 90% at willingness-to-pay of about £1400 (Figure 1).
There are no established willingness-to-pay thresholds for QoL-AD
against which to compare this ﬁnding, but for a 1-point difference
on a 40-point scale, a cost of only £1400 looks modest.
Based on previous studies,2 the effect size of “standard” CST on
QoL-AD scale is 0.4 SD, which is a modest increment. In this study the
difference at follow-up for MCST was 1.78 points (0.34 SD). A 2-point
difference in QoL-AD can be considered clinically signiﬁcant, and
costs only £2800 to achieve.
For ADAS-Cog, the probability that MCST would be seen as cost-
effective was low across all willingness-to-pay values (Figure 2).
Fig. 1. Cost-effectiveness acceptability curve: MCST vs usual care; 6 months, health
and social care perspective, with effectiveness measured on the QoL-AD scale.
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MMSE, the cost-effectiveness analyses suggest that MCST would be a
cost-effective addition to usual care at low willingness-to-pay
thresholds. Howard et al19 suggested that a difference of 1.4 on
MMSE is clinically signiﬁcant; the mean cost of achieving this dif-
ference through MCST is £781.
When QALYs were measured using proxy EQ-5D ratings, mean
ICER was £26,835; from the CEAC the probability that MCST would be
cost-effective was 40% at the £20,000 threshold associated with
National Institute for Health and Clinical Excellence (NICE) recom-
mendations, and 54% at the £30,000 threshold.25 For none of the
other QALY measures was there evidence that MCST would be cost-
effective (Table 3).Interaction With Use of ACHEIs
Examination of the impact of ACHEI use on the effectiveness of
MCST found no signiﬁcant differences in outcomes except MMSE,
adjusting for baseline covariates.5 Participants taking ACHEI medi-
cations randomized to MCST had the smallest decline in cognitiveFig. 2. Cost-effectiveness acceptability curve: MCST vs usual care; 6 months, health
and social care perspective, with effectiveness measured on the ADAS-Cog scale.functioning; participants taking ACHEIs randomized to usual
careeonly had the largest.
Total health and social care (including intervention) costs over
6 months were £7248 for participants randomized to MCST taking
ACHEIs, £13,482 for participants randomized to MCST not taking
ACHEIs, £9256 for the usual care group taking ACHEIs, and £12,381 for
the usual care group not taking ACHEIs. On average, individuals not
taking ACHEIs made greater use of health and social care resources.
An interaction term for MCST and ACHEI in the SUR regressions
showed a positive interaction between MCST and ACHEI for MMSE,
signiﬁcant at 3 months (bootstrapped coefﬁcient ¼ 2.39, P ¼ .06) and
almost signiﬁcant at 6 months (bootstrapped coefﬁcient ¼ 2.63,
P ¼ .11). Mean ICERs are reported in Table 3. By reference to self-
reported and proxy-rated EQ-5D, MCST in combination with ACHEI
appears more cost-effective than ACHEI treatment with usual care,
with mean ICERs below the NICE £20,000 threshold.25
Sensitivity Analyses
We repeated the analyses from a societal perspective. When
looking at unadjusted differences, unpaid carer costs were not
signiﬁcantly higher at 5% level for the MCST group compared with the
usual careeonly group over 6 months (Table 2). Adjusted differences
were not signiﬁcant for most aggregates, with the exception of pre-
baseline unpaid carer and total costs.
Estimated ICERs from the societal perspective show that usual
care dominated MCST when looking at ADAS-Cog (Table 3). For QoL-
AD, the estimated ICER was £643 over 6 months. Assuming MCST
costs more closely resembling those in standard practice showed that
MCST was more cost-effective than usual care (Table 3). In particular,
the ICER for QoL-AD decreased to £68 over 6 months. Among sec-
ondary outcomes, the ICER was £143 for each 1-point difference on
MMSE and £126 for each 1-point difference on ADCS-ADL. Cost per
QALY was quite low: £6,841 when generated from proxy-rated EQ-5D
and £7666 from proxy-rated DEMQOL over 6 months.
Discussion
Summary
Previous studies show that CST is effective in improving cognition
and quality of life2 and cost-effective.3 CST is endorsed in NICE clinical
guidelines.6 Orrell et al5 showed that people with dementia receiving
CST who then continue with the therapy for another 24 weeks had
better quality of life at 6 months compared with people who instead
continued with usual care. Adjusting for baseline covariates, health
and social care costs for MCST were slightly although not statistically
signiﬁcantly higher than for usual careeonly.
The 2 primary outcomes for the trial were quality of life measured
by QoL-AD and cognition measured by ADAS-Cog. On the former,
MCST was cost-effective compared with usual care at 6 months; on
the latter, MCST was not cost-effective at 6 months.
Four of 8 secondary outcome measures in the study were QALY
measures. Results were mixed. MCST was cost-effective for cognition
measured by MMSE, ability in ADLs, and proxy-rated quality of life
measured by proxy QoL-AD and proxy DEMQOL. For QALYs calculated
from proxy EQ-5D, MCST was also cost-effective against the NICE
threshold of £30,000 per QALY. For the remaining 3 QALY outcomes,
MCST was not cost-effective at 6 months.
Sensitivity analyses conducted from a societal perspective again
produced mixed cost-effectiveness ﬁndings.
Subgroup analyses found that combining MCST and ACHEI was
more cost-effective than ACHEI and usual care by reference to a
number of outcomes, including cost per QALY.
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There is only 1 previous economic evaluation of CST: CST delivered
twice-weekly over 7 weeks was cost-effective, with mean cost per
incremental difference in MMSE of £75, and mean cost per incre-
mental difference in QoL-AD of £23 (from a health and social care
perspective).3 In the present study, cost per incremental difference on
these same 2 measures at 6 months, even allowing for price inﬂation
over time, was much higher (£558 and £266, respectively). The earlier
study also found a signiﬁcant improvement in cognition measured by
ADAS-Cog; there was no similar difference in our new study. These
results may arise because the usual care group in the current study
continued to experience beneﬁts from their initial 7 weeks of CST.
Although based on relatively few studies, the Cochrane review of
cognitive stimulation2 suggested that beneﬁts in terms of cognition
were evident, for example, 3 months after the end of CST.
Although there have been numerous economic studies of medi-
cations for treating dementia,26 none has looked at interactions with
CST to allow comparison with the present trial.
Strengths and Limitations
Orrell et al5 discuss a number of strengths and limitations of the
trial. One limitation of the economic analysis is that unpaid carers or
care staff who completed proxy ratings were not blind to treatment
allocation, opening up the risk of detection bias. Some cost-
effectiveness advantages found for MCST, at 3 and 6 months, were
based on proxy ratings.
Studies that compare usual care with an intervention added to
usual care, and which recruit across multiple sites, have the advan-
tage that “usual care” potentially reﬂects a range of treatment and
care arrangements, making it easier to generalize ﬁndings to other
contexts. On the other hand, variation in what constitutes “usual
care” between sites may affect outcomes and costs. However, there
was no site-related imbalance in the randomization procedure in this
pragmatic trial, and the cost-effectiveness analyses adjusted for site.
A common limitation of economics studies in the dementia ﬁeld is
uncertainty surrounding the costing of unpaid care. It is inherently
difﬁcult to measure time spent supporting someone with dementia,
and there are various ways to attach costs to that time. These un-
certainties only affect analyses from a societal perspective.
The EQ5D and DEMQOL-based QALY measures do not provide
consistent cost-effectiveness ﬁndings. This is not unexpected, because
EQ-5D is a generic quality-of-life indicator, whereas DEMQOL is
dementia-speciﬁc. Previous studies have shown that for people with
dementia, self-rated and proxy quality-of-life measures often have
low levels of overall agreement and therefore cannot be assumed to
substitute for each other (eg, Arons et al27). For these reasons, we
have reported results using both approaches.
Implications for Policy and Practice
The importance of promoting new strategies for improving care
and support for people with dementia was highlighted in the formal
declaration from the G8 Dementia Summit, December 2013: “We
[Health and Science Ministers] . call for greater innovation to
improve the quality of life for people with dementia and their carers
while reducing emotional and ﬁnancial burden.” Our new study of
the cost-effectiveness of maintenance CST contributes modestly to
the evidence base.
The economic case for continuing CST beyond an initial 7-week
twice-weekly program is mixed. Although maintenance CST did not
increase health and social care costs (or costs of unpaid care),
outcome gains were modest over 6 months. On economic grounds, acase could be argued for adding MCST to usual care if the outcomes of
primary concern are self-rated quality of life, interviewer-rated
cognition (measured by MMSE), or proxy-rated QALYs (from the
EQ-5D). But the economic case for MCST cannot be made by reference
to other outcomes: it was not that MCST participants fared less well
as assessed by those other measures, but that the small (even if
insigniﬁcant) increase in costs associated with MCST did not appear
to be justiﬁed by the outcomes. Following a research stream re-
commended by NICE, we found that combining MCST with ACHEI
medication has economic advantages over ACHEI with usual care
alone. Moreover, MCST looks more cost-effective than usual care
when costs are used that more closely resemble those in standard
practice. Rolling out MCST more widely (beyond the research context)
might therefore have economic advantages, although we do not know
from this study whether outcomes would be different.Acknowledgments
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